RANDOMIZED TRIAL COMPARING ADRIAMYCIN VINCRISTINE (AV) CYCLOPHOSPHAMIDE METHOTREXATE 5-FLUOROURACIL PREDNISONE (CMFP) HYBRID VERSUS AV-CMFP MONTHLY ALTERNATED IN METASTATIC BREAST-CANCER

  • Authors:
    • CT VALLEJO
    • AA BIANCO
    • JE PEREZ
    • MR MACHIAVELLI
    • BA LEONE
    • AR ROMERO
    • MG RABINOVICH
    • LA ALVAREZ
    • R RODRIGUEZ
    • MA CUEVAS
    • A HANNOIS
    • JA LACAVA
  • View Affiliations

  • Published online on: March 1, 1993     https://doi.org/10.3892/ijo.2.3.437
  • Pages: 437-442
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

194 metastatic breast cancer patients with no prior chemotherapy for advanced disease were randomized to one of two alternating schedules, fulfilling the requisites of Goldie and Coldman's hypothesis to evaluate if the earlier alternation of two non-cross resistant regimens is superior in terms of response (R), duration of R (DR), and survival (SV). Treatment: arm A: Adriamycin (A) 60 mg/m2 IV day (d) 1 and vincristine (V) 1.4 mg/m2 IV d 1 and 8 monthly alternated with cyclophosphamide (C) 100 mg/m2 p.o. d 1-14; methotrexate (M) 30 mg/m2 IV d 1 and 8; 5-fluorouracil (F) 600 mg/m2 IV d 1 and 8 and prednisone (Pr) 40 mg/m2 p.o. d 1-14. Arm B (hybrid): A 60 mg/m2 IV d 1; V 1.4 mg/m2 IV d 1; C 100 mg/m2 p.o. d 8-14; M 30 mg/m2 IV d 8; F 600 mg/m2 IV d 8 and Pr 40 mg/m2 p.o. d 8-14. Results: 87 and 89 patients are evaluable for R. Arm A: R= 59% (51/87); median DR= 13 months (m); median SV= 25 m. Arm B: R= 69% (61/89); median DR= 15 m.; median SV= 29 m. Myelosuppression was slightly more marked in arm B. Three patients had toxic-related deaths (arm A: 1; arm B: 2). Conclusions: a trend favoring an earlier alternation and higher dose intensity (DI) was found regarding to R, DR and SV. However, differences were not statistically significant.

Related Articles

Journal Cover

March 1993
Volume 2 Issue 3

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
VALLEJO C, BIANCO A, PEREZ J, MACHIAVELLI M, LEONE B, ROMERO A, RABINOVICH M, ALVAREZ L, RODRIGUEZ R, CUEVAS M, CUEVAS M, et al: RANDOMIZED TRIAL COMPARING ADRIAMYCIN VINCRISTINE (AV) CYCLOPHOSPHAMIDE METHOTREXATE 5-FLUOROURACIL PREDNISONE (CMFP) HYBRID VERSUS AV-CMFP MONTHLY ALTERNATED IN METASTATIC BREAST-CANCER. Int J Oncol 2: 437-442, 1993.
APA
VALLEJO, C., BIANCO, A., PEREZ, J., MACHIAVELLI, M., LEONE, B., ROMERO, A. ... LACAVA, J. (1993). RANDOMIZED TRIAL COMPARING ADRIAMYCIN VINCRISTINE (AV) CYCLOPHOSPHAMIDE METHOTREXATE 5-FLUOROURACIL PREDNISONE (CMFP) HYBRID VERSUS AV-CMFP MONTHLY ALTERNATED IN METASTATIC BREAST-CANCER. International Journal of Oncology, 2, 437-442. https://doi.org/10.3892/ijo.2.3.437
MLA
VALLEJO, C., BIANCO, A., PEREZ, J., MACHIAVELLI, M., LEONE, B., ROMERO, A., RABINOVICH, M., ALVAREZ, L., RODRIGUEZ, R., CUEVAS, M., HANNOIS, A., LACAVA, J."RANDOMIZED TRIAL COMPARING ADRIAMYCIN VINCRISTINE (AV) CYCLOPHOSPHAMIDE METHOTREXATE 5-FLUOROURACIL PREDNISONE (CMFP) HYBRID VERSUS AV-CMFP MONTHLY ALTERNATED IN METASTATIC BREAST-CANCER". International Journal of Oncology 2.3 (1993): 437-442.
Chicago
VALLEJO, C., BIANCO, A., PEREZ, J., MACHIAVELLI, M., LEONE, B., ROMERO, A., RABINOVICH, M., ALVAREZ, L., RODRIGUEZ, R., CUEVAS, M., HANNOIS, A., LACAVA, J."RANDOMIZED TRIAL COMPARING ADRIAMYCIN VINCRISTINE (AV) CYCLOPHOSPHAMIDE METHOTREXATE 5-FLUOROURACIL PREDNISONE (CMFP) HYBRID VERSUS AV-CMFP MONTHLY ALTERNATED IN METASTATIC BREAST-CANCER". International Journal of Oncology 2, no. 3 (1993): 437-442. https://doi.org/10.3892/ijo.2.3.437